Simulating an Immune Response with a Combined Agent-Based Model of a Triple-Negative Breast Cancer Tumor and Vascular Network

Cytotoxic T-cells (CTLs) are one mechanism the immune system employs to eliminate cancer cells. In this study, we expand upon a previous 3-dimensional agent-based model of triple-negative breast cancer to include an immuno-therapy in the form of a CTL insertion into the tumor. The model consists of a triple-negative breast tumor, comprised of progenitor cells, cancer stem cells, tumor-associated macrophages, as well as an expanding vascular network. We investigate the treatment effects of inserting different numbers of CTLs into the tumor microenvironment, and their overall effect on tumor size in the short and longer terms. The results show that while CTLs decrease the size of the tumor they are ineffective at completely eliminating it, leading to continued tumor proliferation in the aftermath.

[1]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[2]  A. Popel,et al.  Lymphatic endothelial cells support tumor growth in breast cancer , 2014, Scientific Reports.

[3]  A. Orekhov,et al.  Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis , 2014, Front. Physiol..

[4]  Peter P. Lee,et al.  Modeling Protective Anti-Tumor Immunity via Preventative Cancer Vaccines Using a Hybrid Agent-based and Delay Differential Equation Approach , 2012, PLoS Comput. Biol..

[5]  J. Altman,et al.  Characteristics of virus-specific CD8(+) T cells in the liver during the control and resolution phases of influenza pneumonia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J.E.L. Desautels,et al.  Shape factors for analysis of breast tumors in mammograms , 1996, Proceedings of 1996 Canadian Conference on Electrical and Computer Engineering.

[7]  Sebastian Amigorena,et al.  In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor , 2007, The Journal of experimental medicine.

[8]  Andrew M. Colman,et al.  The complexity of cooperation: Agent-based models of competition and collaboration , 1998, Complex..

[9]  F. Luscinskas,et al.  Acquisition of Selectin Binding and Peripheral Homing Properties by CD4+ and CD8+ T Cells , 1999, The Journal of experimental medicine.

[10]  D. McDonald,et al.  Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.

[11]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[12]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[13]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[14]  I. Fidler,et al.  AACR centennial series: the biology of cancer metastasis: historical perspective. , 2010, Cancer research.

[15]  Lai Guan Ng,et al.  Random migration precedes stable target cell interactions of tumor-infiltrating T cells , 2006, The Journal of experimental medicine.

[16]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[17]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[18]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Shasha Liu,et al.  Fates of CD8+ T cells in Tumor Microenvironment , 2018, Computational and structural biotechnology journal.

[20]  G. Parmiani.  Tumor-infiltrating T cells--friend or foe of neoplastic cells? , 2005, The New England journal of medicine.

[21]  P. Loehrer.  Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer , 2007 .

[22]  D. Wood,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer Screening. , 2015, Thoracic surgery clinics.

[23]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[24]  A. Popel,et al.  Modeling triple-negative breast cancer heterogeneity: Effects of stromal macrophages, fibroblasts and tumor vasculature. , 2018, Journal of theoretical biology.

[25]  Ridgway Pf.  Tumours : wounds that do not heal. , 2002 .

[26]  Eric Bonabeau,et al.  Agent-based modeling: Methods and techniques for simulating human systems , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  F. M. Gabhann,et al.  Systems Biology of Vascular Endothelial Growth Factors , 2008, Microcirculation.

[28]  Aleksander S Popel,et al.  Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. , 2014, Cytokine & growth factor reviews.

[29]  A. Tager,et al.  Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues , 2003, Nature Immunology.

[30]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[31]  T. Ley,et al.  How do cytotoxic lymphocytes kill their targets? , 1998, Current opinion in immunology.

[32]  M. Blasco.  Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.

[33]  Y. Shyr,et al.  Transforming Growth Factor-β Signaling–Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion , 2008, Molecular Cancer Research.

[34]  S. Tyldesley,et al.  Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed , 2017, Breast Cancer Research and Treatment.

[35]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[36]  Aleksander S. Popel,et al.  Effects of endothelial cell proliferation and migration rates in a computational model of sprouting angiogenesis , 2016, Scientific Reports.

[37]  Jeremy J. W. Chen,et al.  Tumor-Associated Macrophage: Its Role in Cancer Invasion and Metastasis , 2006 .

[38]  H. Dvorak,et al.  Heterogeneity of the Tumor Vasculature , 2010, Seminars in thrombosis and hemostasis.

[39]  Wolfgang Weninger,et al.  Migratory Properties of Naive, Effector, and Memory Cd8+ T Cells , 2001, The Journal of experimental medicine.

[40]  Peter Carmeliet,et al.  VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.

[41]  Laird Ak.  DYNAMICS OF TUMOR GROWTH. , 1964 .

[42]  M. Lisanti,et al.  CCR5 antagonist blocks metastasis of basal breast cancer cells. , 2012, Cancer research.

[43]  H. Hiratsuka,et al.  Tumor‐infiltrating CD8+ T‐cell density is an independent prognostic marker for oral squamous cell carcinoma , 2019, Cancer medicine.

[44]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[45]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[46]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[47]  Aleksander S. Popel,et al.  An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia , 2017, BMC Systems Biology.

[48]  Randolph W. Hall,et al.  Discrete models/continuous models , 1986 .

[49]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[50]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[51]  Gerhard Christofori,et al.  The angiogenic switch in carcinogenesis. , 2009, Seminars in cancer biology.